REGENXBIO Inc.

Healthcare · Biotechnology · United States

Last price 7.41 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 489.16M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12...